Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Down 40.7% in April

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totaling 586,422 shares, a decrease of 40.7% from the April 15th total of 988,346 shares. Based on an average daily trading volume, of 189,024 shares, the short-interest ratio is currently 3.1 days. Approximately 5.9% of the company’s stock are sold short.

Cocrystal Pharma Stock Down 4.8%

COCP traded down $0.06 during trading on Friday, hitting $1.20. 101,244 shares of the company’s stock were exchanged, compared to its average volume of 150,678. The business’s 50 day moving average is $1.27 and its two-hundred day moving average is $1.11. Cocrystal Pharma has a fifty-two week low of $0.86 and a fifty-two week high of $2.67. The stock has a market cap of $16.55 million, a P/E ratio of -1.64 and a beta of 1.50.

Cocrystal Pharma (NASDAQ:COCP) last released its quarterly earnings data on Thursday, May 21st. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The business had revenue of $0.22 million for the quarter. On average, sell-side analysts forecast that Cocrystal Pharma will post -0.67 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC acquired a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned about 0.24% of Cocrystal Pharma at the end of the most recent quarter. Institutional investors and hedge funds own 6.72% of the company’s stock.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.